⌕
Pacira BioSciences · PCRX · Nasdaq
Tenet 56 · Mixed
Compare
$36.48+0.05%At closeTenet 56 · Mixed
$36.48+0.02 (+0.05%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Pacira BioSciences (PCRX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is PCRX's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● PRNewsWireNov 17, 2026 · 08:50 ET
Viatris Completes Acquisition of Pacira BioSciences

PITTSBURGH, Nov. 17, 2026 /PRNewswire/ -- Viatris Inc. ("Viatris") (Nasdaq: VTRS), a global healthcare company, today announced that it has completed its acquisition of Pacira BioSciences, Inc. ("Pacira") (Nasdaq: PCRX),…

PCRX 0.0% todayRead at source ↗
● PRNewsWireNov 11, 2026 · 18:51 ET
Ingram Micro Holding Set to Join S&P SmallCap 600

NEW YORK, Nov. 11, 2026 /PRNewswire/ -- Ingram Micro Holding Corp. (NYSE: INGM) will replace Pacira BioSciences Inc. (NASD: PCRX) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, November 17.…

PCRX 0.0% todayRead at source ↗
● Business WireNov 5, 2026 · 17:01 ET
Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pacira BioSciences, Inc. …

PCRX 0.0% todayRead at source ↗
● PRNewsWireNov 5, 2026 · 06:59 ETEARNINGS EXPECTED BY FEB 16
Viatris Reports Third-Quarter 2026 Financial Results

Delivers Total Revenues of $3.75 Billion, U.S. GAAP Net Loss of $325 Million and Adjusted EBITDA of $1.20 Billion Receives Regulatory Approval for RYZUMVI® for Presbyopia in the U.S. and WAKIX® in Japan Returns Approxima…

PCRX 0.0% todayRead at source ↗
● GlobeNewsWireNov 4, 2026 · 08:16 ET
INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger – RRC, SGRY, BOLT and PCRX - IS IT A FAIR DEAL FOR YOU?

NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney  Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a …

PCRX 0.0% todayRead at source ↗
● PRNewsWireNov 3, 2026 · 19:09 ET
Are BWIN, LFCR, PCRX Obtaining Fair Deals for their Shareholders?

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws…

PCRX 0.0% todayRead at source ↗
● Business WireOct 31, 2026 · 07:10 ET
PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Pacira BioSciences, Inc. (NASDAQ: PCRX) to Viatris Inc. for $36.50 per share in cash. Halper Sadeh encourages Pacira …

PCRX 0.0% todayRead at source ↗
● PRNewsWireOct 30, 2026 · 08:40 ET
Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.

PITTSBURGH, Oct. 30, 2026 /PRNewswire/ -- Viatris Inc. ("Viatris") (Nasdaq: VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, has comme…

PCRX 0.0% todayRead at source ↗
● GuruFocusOct 12, 2026 · 21:00 ET
Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?

Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Oct. 12, 2026Insiders may stand to receive substantial financial bene…

PCRX 0.0% todayRead at source ↗
● Business WireOct 12, 2026 · 12:43 ET
Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pacira BioSciences, Inc. …

PCRX 0.0% todayRead at source ↗
● PRNewsWireOct 11, 2026 · 12:30 ET
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX)

NEW YORK, Oct. 11, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top …

PCRX 0.0% todayRead at source ↗
● Zacks Investment ResearchOct 9, 2026 · 11:40 ET
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio

VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.…

PCRX 0.0% todayRead at source ↗
● Newsfile CorpOct 8, 2026 · 17:52 ET
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pacira BioSciences, Inc. (PCRX)

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - October 8, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Pacira BioSciences, Inc. ("Pacira BioSci…

PCRX 0.0% todayRead at source ↗
● GuruFocusOct 8, 2026 · 13:00 ET
PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.

PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.PR NewswireMILWAUKEE, Oct. 8, 2026PCRX shareholders will rec…

PCRX 0.0% todayRead at source ↗
● Schaeffers ResearchOct 8, 2026 · 11:23 ET
2 Stocks Drawing Bearish Options Activity Today

Options traders are taking a bearish stance on two stocks attracting unusual volume today: Pacira BioSciences Inc (NASDAQ:PCRX) and Ring Energy Inc (NYSEAMERICAN:REI).…

PCRX 0.0% todayRead at source ↗
● GuruFocusOct 8, 2026 · 09:00 ET
PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Pacira BioSciences, Inc. (NASDAQ: PCRX) to Viatris Inc. for $36.50 per share in cash…

PCRX 0.0% todayRead at source ↗
● WSJOct 8, 2026 · 08:48 ET
Viatris to Buy Pacira BioSciences for $1.65 Billion

Viatris has agreed to buy pain-drug maker Pacira BioSciences for $1.65 billion in a deal that expands the healthcare company's medicines portfolio.…

PCRX 0.0% todayRead at source ↗
● PRNewsWireOct 8, 2026 · 07:45 ET
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies

Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products' Reach Across Selected Markets Within Its International Infrastructure Expands U.S. Innov…

PCRX 0.0% todayRead at source ↗
● GlobeNewsWireOct 7, 2026 · 08:00 ET
Pacira BioSciences and Caregiver Action Network Announce New Survey on Gaps in Preparing Families for Postsurgical Recovery at Home

Caregivers say they need clearer pain management plans, earlier education, and practical support on non-opioid options before a loved one undergoes surgery BRISBANE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSc…

PCRX 0.0% todayRead at source ↗

No recent releases where the company itself is speaking.

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 16. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

ANT13
NVDA11−2.9%
SPCX4+1.3%
BNO3−1.6%

Article counts from the last market-wide feed page, across every symbol we track and not just PCRX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.